Trends and perspectives for improving quality of chronic kidney disease care: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Journal: Kidney international
Published Date:

Abstract

Chronic kidney disease (CKD) affects over 850 million people globally, and the need to prevent its development and progression is urgent. During the past decade, new perspectives have arisen related to the quality and precision of care for CKD, owing to the development of new tools and interventions for CKD diagnosis and management. New biomarkers, imaging methods, artificial intelligence techniques, and approaches to organizing and delivering healthcare may help clinicians recognize CKD, determine its etiology, assess the dominant mechanisms at given time points, and identify patients at high risk for progression or related events. As opportunities to apply the concepts of precision medicine for CKD identification and management continue to be developed, an ongoing discussion of the potential implications for care delivery is required. The 2022 KDIGO Controversies Conference on Improving CKD Quality of Care: Trends and Perspectives examined and discussed best practices for improving the precision of CKD diagnosis and prognosis, managing the complications of CKD, enhancing the safety of care, and maximizing patient quality of life. Existing tools and interventions currently available for the diagnosis and treatment of CKD were identified, with discussion of current barriers to their implementation and strategies for improving the quality of care delivered for CKD. Key knowledge gaps and areas for research were also identified.

Authors

  • Kai-Uwe Eckardt
    Department of Nephrology and Medical Intensive Care, Charité-Universitätsmedizin Berlin, Berlin, Germany. Electronic address: kai-uwe.eckardt@charite.de.
  • Cynthia Delgado
    Division of Nephrology, University of California, San Francisco, San Francisco, California, USA; Nephrology Section, San Francisco Veterans Affairs Medical Center, San Francisco, California, USA.
  • Hiddo J L Heerspink
    Department of Clinical Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; The George Institute for Global Health, Sydney, Australia.
  • Roberto Pecoits-Filho
    Arbor Research Collaborative for Health, Ann Arbor, Michigan.
  • Ana C Ricardo
    Division of Nephrology, Department of Medicine, University of Illinois Chicago, Chicago, Illinois, USA.
  • Bénédicte Stengel
    French Institute of Health and Medical Research (INSERM), Villejuif, France.
  • Marcello Tonelli
    Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Michael Cheung
    Kidney Disease: Improving Global Outcomes (KDIGO), Brussels, Belgium.
  • Michel Jadoul
    Cliniques Universitaires Saint Luc, Université Catholique de Louvain, Brussels, Belgium.
  • Wolfgang C Winkelmayer
    Selzman Institute for Kidney Health, Section of Nephrology, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
  • Holly Kramer
    Division of Nephrology, Departments of Medicine and Public Health Sciences, Loyola University, Maywood, IL.